Synteract acquires KinderPharm to be ‘one-stop shop’ for pediatric clinical trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/KatarzynaBialasiewicz)
(Image: Getty/KatarzynaBialasiewicz)

Related tags: Synteract, KinderPharm, Pediatrics, Drug development, Clinical trials

Synteract’s clients will benefit from a single source model, says CEO, following the acquisition of KinderPharm, a PA-based CRO focused on all phases of pediatric drug development.

Synteract CEO Steve Powell said the combined contract research organization (CRO) will offer biopharma a “one-stop shop solution for bringing their pediatric clinical trials​ to life.”

“Through the KinderPharm integration, our clients will be able to benefit from a single source model,” ​Powell told us.

The single source model will offer pharmacometric modeling and clinical trial simulation technologies, including pharmacokinetic data analysis, PK/PD modeling, physiologically-based PK modeling, and population PK analysis.

Powell added, “KinderPharm also brings a focus on the development of novel and rare pediatric drugs through pediatric formulation and juvenile toxicology expertise, as well as extensive US and European pediatric regulatory experience.”

Martin Graham, PhD, KinderPharm CEO and founder, will join the team as senior vice president of pediatric development, leading Synteract’s Center of Pediatric Development. 

Graham will be joined by KinderPharm’s Lynne Georgopoulos, vice president pediatric development, Americas, and Synteract’s Dr. Martine Dehlinger-Kremer, vice president pediatric development, Europe, to build a leadership team.

Synteract earlier this year announced​ pediatrics as one of its “therapeutic centers of development.”​ Other centers include oncology, neuro-degenerative disorders, rare and orphan diseases, as well as dermatology – following the acquisition​ of Cu-Tech in July.

KinderPharm was previously involved in a strategic alliance with Worldwide Clinical Trials​ (WCT). Announced in April of this year, the alliance established a center of excellence for pediatric drug development and research. The relationship had since been dissolved.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more